Brokerage Reports
Arvinas, Inc. [ARVN]
Reports for Purchase
Showing records 41 - 60 ( 210 total )
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Price: 25.00
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; Alignment on 1L ARV-471 + Palbo Ph 3
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Price: 12.50
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Thoughts on Dose Selection for First-Line Phase 3 Combo Trial with Palbociclib; Reit. Buy and $90 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 12.50
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Price: 12.50
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Frontline Ph 3 Delay with Study Amendment; PT to $27
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Price: 12.50
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Price: 25.00
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
VERITAC Data Leaves Scope for Improvement in the Pivotal Trial
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 5.00
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
VERITAC Ph 2 Data Consistent with Expectations; Ph 3 Designed with Co-Primaries
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Price: 12.50
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Price: 12.50
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
EMERALD Might Guide the Development of ARV-471; Reit Buy and PT $90
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 12.50
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Price: 12.50
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Game, Set and Match for SERENA-2 in Late Stage BC
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Price: 5.00
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - Relevant Abstracts at EORTC-NCI-AACR 2022
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Price: 12.50
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Price: 12.50
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; VERITAC Data Ahead; No Quick Route for Bavdeg
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Price: 12.50
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Bavdegalutamide (ARV-110) Might Start the Era of Precision Medicine in TPD Landscape; Reit. Buy; Lower PT to $90
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 12.50
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare Coverage Update - Dropping Coverage
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Price: 5.00
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
1Q2022 - Cash Balance and Upcoming Catalysts For Our Biotech Coverage Universe
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Price: 12.50
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; Downgrading to NEUTRAL on SERD Studies Pointing to Challenges
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Price: 12.50
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Price: 12.50